RT Journal Article
SR Electronic
T1 SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.19.21249840
DO 10.1101/2021.01.19.21249840
A1 Collier, Dami A.
A1 Marco, Anna De
A1 Ferreira, Isabella A.T.M.
A1 Meng, Bo
A1 Datir, Rawlings
A1 Walls, Alexandra C.
A1 Kemp S, Steven A.
A1 Bassi, Jessica
A1 Pinto, Dora
A1 Fregni, Chiara Silacci
A1 Bianchi, Siro
A1 Tortorici, M. Alejandra
A1 Bowen, John
A1 Culap, Katja
A1 Jaconi, Stefano
A1 Cameroni, Elisabetta
A1 Snell, Gyorgy
A1 Pizzuto, Matteo S.
A1 Pellanda, Alessandra Franzetti
A1 Garzoni, Christian
A1 Riva, Agostino
A1 The CITIID-NIHR BioResource COVID-19 Collaboration
A1 Elmer, Anne
A1 Kingston, Nathalie
A1 Graves, Barbara
A1 McCoy, Laura E
A1 Smith, Kenneth GC
A1 Bradley, John R.
A1 Ceron-Gutierrez L, Lourdes
A1 Barcenas-Morales, Gabriela
A1 The COVID-19 Genomics UK (COG-UK) consortium
A1 Harvey, William
A1 Virgin, Herbert W.
A1 Lanzavecchia, Antonio
A1 Piccoli, Luca
A1 Doffinger, Rainer
A1 Wills, Mark
A1 Veesler, David
A1 Corti, Davide
A1 Gupta, Ravindra K.
YR 2021
UL http://medrxiv.org/content/early/2021/02/03/2021.01.19.21249840.abstract
AB SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 mutations found in the B.1.1.7 Spike protein. The vaccine sera exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralization was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 outof 29), but not in neutralizing mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralizing activity by vaccine-elicited antibodies over that conferred by the B.1.1.7 mutations alone. Further work is needed to establish the impact of these observations on protective vaccine efficacy in the context of the evolving B.1.1.7 lineage.Competing Interest StatementA.D.M., J.B., D.P., C.S.F., S.B., K.C., N.S., E.C., G.S., S.J., A.L., H.W.V., M.S.P., L.P. and D.C. are employees of Vir Biotechnology and may hold shares in Vir Biotechnology. H.W.V. is a founder of PierianDx and Casma Therapeutics. Neither company provided funding for this work or is performing related work. D.V. is a consultant for Vir Biotechnology Inc. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. RKG has received consulting fees from UMOVIS Lab, Gilead and ViiV.Funding StatementThis research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical ScienceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee 17 EE 0025.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author on request